|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ILK |
Gene summary for ILK |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ILK | Gene ID | 3611 |
| Gene name | integrin linked kinase | |
| Gene Alias | HEL-S-28 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q13418 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3611 | ILK | AEH-subject1 | Human | Endometrium | AEH | 1.59e-04 | -2.30e-01 | -0.3059 |
| 3611 | ILK | AEH-subject2 | Human | Endometrium | AEH | 7.86e-03 | -1.64e-01 | -0.2525 |
| 3611 | ILK | AEH-subject3 | Human | Endometrium | AEH | 9.40e-03 | -1.91e-01 | -0.2576 |
| 3611 | ILK | AEH-subject4 | Human | Endometrium | AEH | 1.91e-02 | -2.08e-01 | -0.2657 |
| 3611 | ILK | AEH-subject5 | Human | Endometrium | AEH | 1.39e-05 | -2.51e-01 | -0.2953 |
| 3611 | ILK | EEC-subject1 | Human | Endometrium | EEC | 6.72e-08 | -2.41e-01 | -0.2682 |
| 3611 | ILK | EEC-subject2 | Human | Endometrium | EEC | 9.21e-04 | -1.99e-01 | -0.2607 |
| 3611 | ILK | EEC-subject3 | Human | Endometrium | EEC | 1.47e-17 | -3.49e-01 | -0.2525 |
| 3611 | ILK | EEC-subject4 | Human | Endometrium | EEC | 1.98e-05 | -3.05e-01 | -0.2571 |
| 3611 | ILK | EEC-subject5 | Human | Endometrium | EEC | 8.62e-06 | -3.03e-01 | -0.249 |
| 3611 | ILK | GSM5276934 | Human | Endometrium | EEC | 3.13e-04 | -2.77e-01 | -0.0913 |
| 3611 | ILK | GSM5276935 | Human | Endometrium | EEC | 4.62e-02 | -2.27e-01 | -0.123 |
| 3611 | ILK | GSM5276937 | Human | Endometrium | EEC | 7.46e-03 | -2.84e-01 | -0.0897 |
| 3611 | ILK | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 5.17e-21 | -1.63e-01 | -0.1869 |
| 3611 | ILK | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.43e-22 | -3.49e-01 | -0.1875 |
| 3611 | ILK | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 9.11e-24 | -3.54e-01 | -0.1883 |
| 3611 | ILK | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.13e-26 | -2.48e-01 | -0.1934 |
| 3611 | ILK | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 8.45e-35 | -2.45e-01 | -0.1917 |
| 3611 | ILK | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 2.89e-31 | -3.10e-01 | -0.1916 |
| 3611 | ILK | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.18e-02 | -1.13e-01 | -0.1269 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0030705 | Colorectum | AD | cytoskeleton-dependent intracellular transport | 60/3918 | 195/18723 | 7.56e-04 | 7.59e-03 | 60 |
| GO:00307051 | Colorectum | SER | cytoskeleton-dependent intracellular transport | 44/2897 | 195/18723 | 5.53e-03 | 4.09e-02 | 44 |
| GO:001081015 | Endometrium | AEH | regulation of cell-substrate adhesion | 64/2100 | 221/18723 | 3.85e-13 | 9.62e-11 | 64 |
| GO:002260415 | Endometrium | AEH | regulation of cell morphogenesis | 79/2100 | 309/18723 | 1.04e-12 | 2.24e-10 | 79 |
| GO:00315899 | Endometrium | AEH | cell-substrate adhesion | 87/2100 | 363/18723 | 3.51e-12 | 5.70e-10 | 87 |
| GO:190002410 | Endometrium | AEH | regulation of substrate adhesion-dependent cell spreading | 27/2100 | 57/18723 | 9.07e-12 | 1.43e-09 | 27 |
| GO:004578516 | Endometrium | AEH | positive regulation of cell adhesion | 96/2100 | 437/18723 | 5.50e-11 | 7.18e-09 | 96 |
| GO:003297016 | Endometrium | AEH | regulation of actin filament-based process | 89/2100 | 397/18723 | 9.14e-11 | 1.10e-08 | 89 |
| GO:004206016 | Endometrium | AEH | wound healing | 91/2100 | 422/18723 | 4.85e-10 | 4.61e-08 | 91 |
| GO:190002610 | Endometrium | AEH | positive regulation of substrate adhesion-dependent cell spreading | 20/2100 | 41/18723 | 2.36e-09 | 1.89e-07 | 20 |
| GO:001081116 | Endometrium | AEH | positive regulation of cell-substrate adhesion | 38/2100 | 123/18723 | 3.08e-09 | 2.26e-07 | 38 |
| GO:003295616 | Endometrium | AEH | regulation of actin cytoskeleton organization | 77/2100 | 358/18723 | 1.18e-08 | 7.76e-07 | 77 |
| GO:000716310 | Endometrium | AEH | establishment or maintenance of cell polarity | 54/2100 | 218/18723 | 1.30e-08 | 8.47e-07 | 54 |
| GO:001076910 | Endometrium | AEH | regulation of cell morphogenesis involved in differentiation | 31/2100 | 96/18723 | 2.70e-08 | 1.56e-06 | 31 |
| GO:00301118 | Endometrium | AEH | regulation of Wnt signaling pathway | 71/2100 | 328/18723 | 3.31e-08 | 1.87e-06 | 71 |
| GO:00019529 | Endometrium | AEH | regulation of cell-matrix adhesion | 37/2100 | 128/18723 | 3.58e-08 | 1.99e-06 | 37 |
| GO:003444610 | Endometrium | AEH | substrate adhesion-dependent cell spreading | 33/2100 | 108/18723 | 4.45e-08 | 2.43e-06 | 33 |
| GO:00160499 | Endometrium | AEH | cell growth | 93/2100 | 482/18723 | 1.00e-07 | 4.99e-06 | 93 |
| GO:003253510 | Endometrium | AEH | regulation of cellular component size | 78/2100 | 383/18723 | 1.10e-07 | 5.29e-06 | 78 |
| GO:00072296 | Endometrium | AEH | integrin-mediated signaling pathway | 32/2100 | 107/18723 | 1.24e-07 | 5.80e-06 | 32 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513126 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
| hsa0510026 | Endometrium | AEH | Bacterial invasion of epithelial cells | 32/1197 | 77/8465 | 3.28e-09 | 5.91e-08 | 4.33e-08 | 32 |
| hsa0451015 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
| hsa0521314 | Endometrium | AEH | Endometrial cancer | 18/1197 | 58/8465 | 7.42e-04 | 5.03e-03 | 3.68e-03 | 18 |
| hsa0436010 | Endometrium | AEH | Axon guidance | 39/1197 | 182/8465 | 4.47e-03 | 2.46e-02 | 1.80e-02 | 39 |
| hsa05131111 | Endometrium | AEH | Shigellosis | 78/1197 | 247/8465 | 9.23e-13 | 2.00e-11 | 1.46e-11 | 78 |
| hsa05100111 | Endometrium | AEH | Bacterial invasion of epithelial cells | 32/1197 | 77/8465 | 3.28e-09 | 5.91e-08 | 4.33e-08 | 32 |
| hsa0451016 | Endometrium | AEH | Focal adhesion | 58/1197 | 203/8465 | 4.99e-08 | 7.37e-07 | 5.39e-07 | 58 |
| hsa0521315 | Endometrium | AEH | Endometrial cancer | 18/1197 | 58/8465 | 7.42e-04 | 5.03e-03 | 3.68e-03 | 18 |
| hsa0436013 | Endometrium | AEH | Axon guidance | 39/1197 | 182/8465 | 4.47e-03 | 2.46e-02 | 1.80e-02 | 39 |
| hsa0513127 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
| hsa0510027 | Endometrium | EEC | Bacterial invasion of epithelial cells | 30/1237 | 77/8465 | 1.26e-07 | 1.88e-06 | 1.40e-06 | 30 |
| hsa0451024 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
| hsa0521323 | Endometrium | EEC | Endometrial cancer | 17/1237 | 58/8465 | 2.97e-03 | 1.71e-02 | 1.28e-02 | 17 |
| hsa0436022 | Endometrium | EEC | Axon guidance | 39/1237 | 182/8465 | 7.78e-03 | 3.66e-02 | 2.73e-02 | 39 |
| hsa0513136 | Endometrium | EEC | Shigellosis | 79/1237 | 247/8465 | 1.80e-12 | 3.95e-11 | 2.95e-11 | 79 |
| hsa0510036 | Endometrium | EEC | Bacterial invasion of epithelial cells | 30/1237 | 77/8465 | 1.26e-07 | 1.88e-06 | 1.40e-06 | 30 |
| hsa0451034 | Endometrium | EEC | Focal adhesion | 58/1237 | 203/8465 | 1.61e-07 | 2.30e-06 | 1.71e-06 | 58 |
| hsa0521333 | Endometrium | EEC | Endometrial cancer | 17/1237 | 58/8465 | 2.97e-03 | 1.71e-02 | 1.28e-02 | 17 |
| hsa0436032 | Endometrium | EEC | Axon guidance | 39/1237 | 182/8465 | 7.78e-03 | 3.66e-02 | 2.73e-02 | 39 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ILK | SNV | Missense_Mutation | c.903N>A | p.Met301Ile | p.M301I | Q13418 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| ILK | SNV | Missense_Mutation | c.1096G>A | p.Glu366Lys | p.E366K | Q13418 | protein_coding | tolerated(0.14) | benign(0.066) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
| ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ILK | SNV | Missense_Mutation | rs752302392 | c.62N>G | p.Asp21Gly | p.D21G | Q13418 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| ILK | SNV | Missense_Mutation | c.539N>C | p.Gly180Ala | p.G180A | Q13418 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| ILK | SNV | Missense_Mutation | novel | c.606T>G | p.Asn202Lys | p.N202K | Q13418 | protein_coding | tolerated(0.11) | benign(0.212) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| ILK | SNV | Missense_Mutation | rs752932911 | c.239N>A | p.Arg80His | p.R80H | Q13418 | protein_coding | tolerated(0.49) | benign(0.017) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine | |||
| 3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine | |||
| 3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | inhibitor | 249565796 | ||
| 3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |